Latest Features from The Ruesch Center

• Why the High CRC Rate in Latino--Genes, Stigma, or Other Factors?   Colorectal cancer is the second most common cause of cancer death in the Latino population. Drs John Marshall and Marcia Cruz-Correa discuss which factors are at play.
  Ruesch Center, March 20, 2017
• Colorectal Cancer in Young Adults: An 'Issue Screaming for Action'   Dr John Marshall speaks to Dr Thomas Weber about the increasing incidence of colorectal cancer in young adults and simple steps that clinicians can take to slow this disturbing trend.
  Ruesch Center, January 30, 2017
• Oncology and Politics: How Long Will the Honeymoon Last? A commentary on Joe Biden's Moonshot address at ASCO and what it will really take to make the initiative successful.
  Ruesch Center, June 27, 2016
• Tumor 'Profiling' Takes on New Significance in GI Cancer Dr Brandon Smaglo reviews key GI cancer presentations from ASCO 2016, finding that growing refinement of tumor subtyping is key to matching patients with effective treatments, including immunotherapy.
  Ruesch Center, June 14, 2016
• 'Releasing the Dogs’ in the Body’s War on Cancer   Drs Lou Weiner and Chris Heery vividly describe strategies that prompt the immune system to attack and kill cancer cells, and offer a view from the trenches of cancer immunotherapy.
  Ruesch Center, February 18, 2016
• Chemo Combos Hit Pancreatic Cancer With Both Barrels A range of therapeutic approaches are beginning to improve patient outcomes and change clinical practice in advanced pancreatic cancer, as reported by Dr Michael Pishvaian from GICS 2016.
  Ruesch Center, February 12, 2016
• PD-1 Inhibitors Show Promise in Upper GI Cancers Early findings suggest that immunotherapies, such as PD-1 inhibitors, could play a large role in the management of upper GI cancers, as reported by Dr Brandon Smaglo from GISC 2016.
  Ruesch Center, February 05, 2016
• Why Is Colorectal Cancer Targeting the Young? The incidence of CRC in persons under 50 is increasing at an incredible pace, prompting experts at the 2015 Ruesch Center Symposium to grapple with how to understand and arrest this disturbing trend.
  Ruesch Center, January 20, 2016
• Will 'Value Vehicle' Drive Cancer Costs Down?   Drs Lowell Schnipper and John Marshall kick the tires of ASCO's 'value vehicle' and assess public response to its 60-day test drive, as part of the 2015 Ruesch Symposium.
  Ruesch Center, December 29, 2015
• Cut Clinical Trial Costs the Smart Way   Dr Daniel Sargent reports that 40% of the costs of clinical trials go to monitoring data, much of which are irrelevant. By revamping monitoring practices, trial costs can be cut substantially.
  Ruesch Center, December 18, 2015
• Stakeholders to Scope Out Value in GI Cancer Therapy   Dr John Marshall previews the upcoming 2015 Ruesch Symposium, in which policy makers, insurers, regulators, researchers, and patients debate about what therapies are worth pursuing in GI cancer.
  Ruesch Center, November 30, 2015
• Value in Cancer Care: But at What Price?   Experts take on the issue of value in cancer care -- among the hottest topics of ASCO 2015 -- and what is at stake if efforts to ensure value do not succeed in containing healthcare costs.
  Ruesch Center, July 13, 2015
• Why Pharma and Oncologists Should Kiss and Make Up Will the cure for cancer be derailed by fiscal unsustainability? An oncologist advocates transparency in costs, which in his view is possible only if Big Pharma and oncologists work cooperatively.
  Ruesch Center, July 07, 2015
• The Frightening Truth About Genetic Testing   Genetic testing is now ordered in the treatment of numerous cancer types. Is it useful? Is it even reliable? Dr John Marshall and world-class experts tackle key questions for practicing clinicians.
  Ruesch Center, June 22, 2015
• Liver-Directed Therapies Increase Survival in mCRC Dr Brandon Smaglo highlights top studies from the GI cancer sessions at ASCO 2015, including liver-directed therapies, new delivery systems, and modalities for agent selection.
  Ruesch Center, June 12, 2015
• Pembrolizumab Boasts Benefit, Tolerability in Gastric Cancer   Dr Brandon Smaglo reports on 2 studies from 2015 GCIS, one showing benefit from pembrolizumab in gastric cancer, another suggesting that less palliative therapy may be warranted in esophageal cancer.
  Ruesch Center, February 03, 2015
• Can Molecular Profiling Lower Cancer Costs?   Dr John Marshall asks tough questions of experts at the 2014 Ruesch Symposium about whether information gained from molecular testing can tailor therapy and lower costs.
  Ruesch Center, December 24, 2014
• Countdown to GI Immunotherapy   How close are we to practice-changing scores that determine a patient's risk and type of treatment needed? Experts at the 2014 Ruesch Symposium estimate that real-time immunotherapy is almost here.
  Ruesch Center, December 24, 2014